Phillip Kiyasu, MD
Gastroenterology · Portland, ORNPI 1124010673
Payments from drug & device makers
What this record shows
This record is dominated by food and beverage: $210 of the $236 with a category attached, or 89.1%. 5 manufacturers reported payments, led by Janssen Scientific Affairs, LLC at 53.0% of the total. 2025 is the largest year on record at $181, 9.4 times the $19 reported in 2023. That places this record below the midpoint for gastroenterology clinicians in OR, where the typical reported total is $455.
Across 5 payments — averaging $47.17 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- Janssen Scientific Affairs, LLC$125
- GSK$35
- Takeda Pharmaceuticals U.S.A., Inc.$31
- Merck$26
- Janssen Research & Development, LLC$19
Across 254 payments — averaging $1928.57 each. Payments tied to a research study. These frequently flow through the physician to a hospital or research institution rather than to the physician personally.
- Janssen Research & Development, LLC$284K
- Genentech, Inc.$146K
- Takeda Pharmaceuticals U.S.A., Inc.$38K
- Regeneron$22K
What the payments were for
- Food & beverage$21089%
- Education$2611%
Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| Janssen Scientific Affairs, LLC | 1 | $125 |
| GSK | 1 | $35 |
| Takeda Pharmaceuticals U.S.A., Inc. | 1 | $31 |
| Merck | 1 | $26 |
| Janssen Research & Development, LLC | 1 | $19 |
How this compares
$236 in reported general payments places this provider in the 35th percentile of 220 gastroenterology providers in Oregon.
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| Mesalamine | 21 | $8,284 |
| Gavilyte-GPeg3350/Sod Sulf,bicarb,cl/Kcl | 86 | $1,569 |
| Sod Sulf-Potass Sulf-Mag SulfSodium, Potassium,mag Sulfates | 21 | $1,443 |
| Budesonide DrBudesonide | 12 | $936 |
| Peg-3350 And ElectrolytesPeg3350/Sod Sulf,bicarb,cl/Kcl | 49 | $887 |
| Omeprazole | 22 | $703 |
| Dicyclomine Hcl | 14 | $523 |
| Gavilyte-CPeg3350/Sod Sulf,bicarb,cl/Kcl | 19 | $311 |
| Pantoprazole Sodium | 24 | $258 |
| Lansoprazole | 12 | $150 |
Paid to pharmacies, not to this prescriber.
Other gastroenterology in Portland
- Donald LumPortland$320K
- Rebecca MatroPortland$154K
- Ian HolmesPortland$102K
- Amy ZhuPortland$72K
- Gregory CotePortland$58K
- Emily JonicaPortland$49K
- Rebecca FauselPortland$29K
- Anil SharmaPortland$14K
- Harry BrayPortland$11K
- Kaveh SharzehiPortland$6K
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.